Nuclear karyopherin α2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity
Open Access
- 17 June 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 123 (6), 1433-1438
- https://doi.org/10.1002/ijc.23628
Abstract
Intensive lymph node involvement indicates poor prognosis in breast cancer patients. The significance of other molecular prognostic factors in this subgroup is unclear. Karyopherin α2 (KPNA2) has been reported as an important factor of tumorgenesis and progression of breast cancer. The aim of present study was to evaluate the impact of KPNA2 expression on prognosis of patients with high risk breast cancer (HRBC) and response intensive chemotherapy within the randomized WSG‐AM‐01 trial. KPNA2 nuclear expression (>10% vs. 9 positive lymph nodes and correlated with clinical outcome (median follow‐up of 63.3 months) by Kaplan–Meier and multivariate Cox hazard model analysis, including, molecular subtypes determined by k‐clustering (k = 5). KPNA2 overexpression (n = 74, 39%) significantly correlated with shorter event‐free and overall survival (OS) in both therapy arms by univariate analysis. Multivariate analysis showed that the overexpression of KPNA2 was an independent prognostic factor of decreased OS HR = 1.86 [95% CI: 1.07–3.23, p = 0.03]. This predictive value was independent of basal‐like/Her‐2/neu subtypes, significantly associated with KPNA2 and was addressed particularly to G2 tumors. Our data suggest the use of KPNA2 nuclear expression as novel prognostic marker in node‐positive patients, especially in determination of G2 tumors in 2 subgroups of different prognosis. KPNA2 expression may be also considered as a marker for global chemoresistance, which can not be overcome by conventional dose‐modification of chemotherapy in advanced breast cancer.Keywords
This publication has 29 references indexed in Scilit:
- Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense ChemotherapyClinical Cancer Research, 2007
- Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer PatientsClinical Cancer Research, 2006
- Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerThe Lancet, 2005
- Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node InvolvementClinical Cancer Research, 2004
- High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized TrialJournal of Clinical Oncology, 2004
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell supportInternational Journal of Cancer, 2002
- Molecular portraits of human breast tumoursNature, 2000
- Localization of BRCA1 and a Splice Variant Identifies the Nuclear Localization SignalMolecular and Cellular Biology, 1997
- Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP updateCancer, 1983